Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas

被引:5
作者
Drakos, Elias
Rassidakis, George Z.
Leventaki, Vasiliki
Guo, Wei
Medeiros, L. Jeffrey
Nagarajan, Lalitha
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA
关键词
MIXL1; homeobox; non-Hodgkin lymphoma; Hodgkin lymphoma;
D O I
10.1016/j.humpath.2006.09.020
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The Mix 1 homeobox-like (MIXL1) gene encodes a paired class homeobox transcription factor that is involved in embryogenesis. Previous studies have shown that the MIXL1 gene product is expressed in B- and T-cell progenitors of normal bone marrow and, in some cell lines derived from hernatopoietic neoplasms. The status of MEW expression in human lymphomas is unknown. Using a highly specific antibody, we assessed for MIXL1 expression and subcellular localization in lymphoma cell lines of B- and T-cell lineage by reverse transcriptase-polymerase chain reaction, Western blot analysis, and immunohistochemistry. We also assessed for MIXL1 expression using immunohistochemical methods in 193 lymphoid tumors, including 140 B-cell non-Hodgkin lymphomas (NHL), 36 T-cell NHL, and 17 Hodgkin lymphomas (HL). MIXL1 was detected predominantly in the nuclear fraction of all cell lines tested and was predominantly nuclear in primary tumor specimens. Based on the distribution of the staining results (histogram), a 50% cutoff was selected for high versus low MIXL1 expression. High MIXL1 expression was detected more frequently in Burkitt lymphoma and diffuse large B-cell lymphoma compared with other types of B-cell NHL (P <.0001, chi(2) test). Most cases of T-cell NHL and all cases of HL also highly expressed MIXL1. Most plasma cell myelomas were negative for MIXL1, but rare cases had low MIXL1 expression. MIXL1 expression significantly correlated with proliferation index (Ki-67) in B-cell NHL (P <.0001). The frequent and high expression of MIXL1 in aggressive B-cell NHL, T-cell NHL, and HL suggests that MIXL1 may be involved in lymphomagenesis. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 50 条
  • [31] Prognostic significance of cyclooxygenase-2 expression in pediatric Hodgkin and non-Hodgkin lymphomas with or without Epstein-Barr virus latent infection
    Aktaş S.
    KargI A.
    Olgun N.
    Diniz G.
    Erbay A.
    Vergin C.
    Comparative Clinical Pathology, 2008, 17 (2) : 125 - 131
  • [32] bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements
    Papakonstantinou, G
    Verbeke, C
    Hastka, J
    Bohrer, M
    Hehlmann, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) : 383 - 390
  • [33] Hepatitis C virus and non-Hodgkin's lymphomas: A minireview
    Khaled, Hussein
    Abu-Taleb, Fouad
    Haggag, Rasha
    JOURNAL OF ADVANCED RESEARCH, 2017, 8 (02) : 131 - 137
  • [34] Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy
    Miyashita, Kaname
    Fujii, Kei
    Yamada, Yu
    Hattori, Hiroyoshi
    Taguchi, Kenichi
    Yamanaka, Takeharu
    Yoshida, Mitsuaki A.
    Okamura, Jun
    Oda, Shinya
    Muta, Koichiro
    Nawata, Hajime
    Takayanagi, Ryoichi
    Uike, Naokuni
    LEUKEMIA RESEARCH, 2008, 32 (08) : 1183 - 1195
  • [35] Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study
    Ternant, David
    Monjanel, Helene
    Venel, Yann
    Prunier-Aesch, Caroline
    Arbion, Flavie
    Colombat, Philippe
    Paintaud, Gilles
    Gyan, Emmanuel
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2002 - 2010
  • [36] Follicular non-Hodgkin lymphomas and minimal residual disease.
    Bruno, S
    MEDICINA-BUENOS AIRES, 2000, 60 : 77 - 82
  • [37] New strategies with Zevalin® consolidation in the treatment of non-Hodgkin lymphomas
    Robu, D.
    Huglo, D.
    Tricot, S.
    Malek, E.
    Jouet, J. -P.
    Morschhauser, F.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (08): : 491 - 498
  • [38] IFOSFAMIDE PLUS MITOXANTRONE AS SALVAGE TREATMENT IN NON-HODGKIN LYMPHOMAS
    LORUSSO, V
    PARADISO, A
    GUIDA, M
    BERARDI, F
    DELENA, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (06): : 492 - 495
  • [39] Biomarkers of susceptibility to chemical carcinogens: the example of non-Hodgkin lymphomas
    Kelly, Rachel S.
    Vineis, Paolo
    BRITISH MEDICAL BULLETIN, 2014, 111 (01) : 89 - 100
  • [40] Non-Hodgkin's lymphomas morbidity in children of Belarus Republic
    Kozarezova, TI
    Kozarezov, SN
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2005, 50 (02): : 13 - 17